Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

Immutep (IMMP) announces it has achieved 50% of the patient enrolment target in the TACTI-004 Phase III trial evaluating eftilagimod alfa in combination with MSD’s anti-PD-1 therapy, Keytruda, and chemotherapy as first line therapy for advanced/metastatic non-small cell lung cancer. Immutep Chief Executive Officer, Marc Voigt, said, “The excellent pace of enrolment globally in the TACTI-004 trial speaks to the promise of efti and the need for more efficacious therapies in the first line setting for patients with advanced/metastatic non-small cell lung cancer. Our team continues to work hard to bring this innovative cancer immunotherapy to market and looks forward to delivering on additional important upcoming milestones ahead, including the futility analysis in the first quarter and completing patient enrolment in the third quarter this year.”